Conmed (EC8) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EC8 Analyst Ratings

Hold

0 Buy

5 Hold

1 Sell

Based on 6 analysts giving stock ratings to

Conmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EC8 Stock 12 Month Forecast

Average Price Target

€38.80

▲(3.18% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Conmed in the last 3 months. The average price target is €38.80 with a high forecast of €39.44 and a low forecast of €38.58. The average price target represents a 3.18% change from the last price of €37.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"€27","46":"€46","31.75":"€31.8","36.5":"€36.5","41.25":"€41.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39.43903978,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€39.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.7960119575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€38.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.58166935,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€38.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,31.75,36.5,41.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.4,40.32607998307692,40.25215996615385,40.17823994923077,40.10431993230769,40.03039991538461,39.95647989846154,39.88255988153846,39.80863986461539,39.73471984769231,39.66079983076923,39.58687981384615,39.51295979692308,{"y":39.43903978,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.4,40.27661630442307,40.15323260884615,40.02984891326923,39.90646521769231,39.78308152211538,39.65969782653846,39.536314130961536,39.41293043538462,39.28954673980769,39.16616304423077,39.042779348653845,38.919395653076926,{"y":38.7960119575,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.4,40.26012841153846,40.12025682307692,39.98038523461538,39.840513646153845,39.700642057692306,39.56077046923077,39.42089888076923,39.28102729230769,39.14115570384615,39.001284115384614,38.861412526923075,38.72154093846154,{"y":38.58166935,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.035,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.829,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.2,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.6,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":31,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€39.44

Average Price Target€38.80

Lowest Price Target€38.58

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robbie Marcus

J.P. Morgan

€34.29→€38.58

Hold

2.61%

Upside

Assigned

07/30/26

Conmed price target raised to $45 from $40 at JPMorganConmed price target raised to $45 from $40 at JPMorgan

Michael Matson

Needham

―

Hold

―

Reiterated

07/30/26

Conmed: Solid 2Q Beat and Higher EPS Guidance, But Trimmed Organic Growth Outlook Keeps Matson at Hold

Larry Biegelsen

Wells Fargo

€33.44→€39.44

Hold

4.89%

Upside

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), Conmed (NYSE: CNMD) and Guardant Health (NASDAQ: GH)

Travis Steed

Bank of America Securities

―

Sell

―

Reiterated

07/30/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Takeda Pharmaceutical Company (NYSE: TAK), Align Tech (NASDAQ: ALGN) and Conmed (NYSE: CNMD)

Matthew O'Brien

Piper Sandler

€33.44→€38.58

Hold

2.61%

Upside

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Boston Scientific (NYSE: BSX), Ionis Pharmaceuticals (NASDAQ: IONS) and Conmed (NYSE: CNMD)

Vik Chopra

BMO Capital

€30.87→€38.58

Hold

2.61%

Upside

Reiterated

07/29/26

BMO Capital Sticks to Their Hold Rating for Conmed (CNMD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robbie Marcus

J.P. Morgan

€34.29→€38.58

Hold

2.61%

Upside

Assigned

07/30/26

Conmed price target raised to $45 from $40 at JPMorganConmed price target raised to $45 from $40 at JPMorgan

Michael Matson

Needham

―

Hold

―

Reiterated

07/30/26

Conmed: Solid 2Q Beat and Higher EPS Guidance, But Trimmed Organic Growth Outlook Keeps Matson at Hold

Larry Biegelsen

Wells Fargo

€33.44→€39.44

Hold

4.89%

Upside

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), Conmed (NYSE: CNMD) and Guardant Health (NASDAQ: GH)

Travis Steed

Bank of America Securities

―

Sell

―

Reiterated

07/30/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Takeda Pharmaceutical Company (NYSE: TAK), Align Tech (NASDAQ: ALGN) and Conmed (NYSE: CNMD)

Matthew O'Brien

Piper Sandler

€33.44→€38.58

Hold

2.61%

Upside

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Boston Scientific (NYSE: BSX), Ionis Pharmaceuticals (NASDAQ: IONS) and Conmed (NYSE: CNMD)

Vik Chopra

BMO Capital

€30.87→€38.58

Hold

2.61%

Upside

Reiterated

07/29/26

BMO Capital Sticks to Their Hold Rating for Conmed (CNMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Conmed

3 Months

PerPlexity Medical - DevicesTipRanks - PerPlexity

Success Rate

1/2 ratings generated profit

Average Return

+7.15%

Copying PerPlexity Medical - Devices's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +7.15% per trade.

1 Year

PerPlexity Medical - DevicesTipRanks - PerPlexity

Success Rate

1/2 ratings generated profit

Average Return

+7.15%

Copying PerPlexity Medical - Devices's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.15% per trade.

2 Years

PerPlexity Medical - DevicesTipRanks - PerPlexity

Success Rate

1/2 ratings generated profit

Average Return

+7.15%

Copying PerPlexity Medical - Devices's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +7.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EC8 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EC8 has received 0 Buy Ratings, 10 Hold Ratings, and 2 Sell Ratings. EC8 average Analyst price target in the past 3 months is 38.80.

Each month's total comprises the sum of three months' worth of ratings.

EC8 Financial Forecast

EC8 Earnings Forecast

Next quarter’s earnings estimate for EC8 is €0.87 with a range of €0.86 to €0.89. The previous quarter’s EPS was €1.20. EC8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EC8 has Performed in-line its overall industry.

EC8 Sales Forecast

Next quarter’s sales forecast for EC8 is €291.77M with a range of €290.51M to €292.59M. The previous quarter’s sales results were €298.28M. EC8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EC8 has Performed in-line its overall industry.

EC8 Stock Forecast FAQ

What is DE:EC8’s average 12-month price target, according to analysts?

Based on analyst ratings, Conmed’s 12-month average price target is 38.80.

What is DE:EC8’s upside potential, based on the analysts’ average price target?

Conmed has 3.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Conmed a Buy, Sell or Hold?

Conmed has a consensus rating of Hold, which is based on 0 buy ratings, 5 hold ratings and 1 sell ratings.

What is Conmed’s share price target?

The average share price target for Conmed is 38.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €39.44 ,and the lowest forecast is €38.58. The average share price target represents 3.18% Increase from the current price of €37.6.

What do analysts say about Conmed?

Conmed’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Conmed?

To buy shares of DE:EC8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Conmed (EC8) Stock Forecast & Price Target

EC8 Analyst Ratings

EC8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Conmed

EC8 Analyst Recommendation Trends

EC8 Financial Forecast

EC8 Earnings Forecast

EC8 Sales Forecast

EC8 Stock Forecast FAQ

Detailed List of Analyst Forecasts